Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Development of Bombesin Analogs with Conformationally Restricted Amino Acid Substitutions with Enhanced Selectivity for the Orphan Receptor Human Bombesin Receptor Subtype 3

Samuel A. Mantey, David H. Coy, Laurence K. Entsuah and Robert T. Jensen
Journal of Pharmacology and Experimental Therapeutics September 2004, 310 (3) 1161-1170; DOI: https://doi.org/10.1124/jpet.104.066761
Samuel A. Mantey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David H. Coy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurence K. Entsuah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert T. Jensen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The human bombesin receptor subtype 3 (hBRS-3) orphan receptor, which has a high homology to bombesin (Bn) receptors [gastrin-releasing peptide (GRP) and neuromedin B (NMB) receptors], is widely distributed in the rat central nervous system. Its natural ligand or role in physiology is unknown due to lack of selective ligands. Its target disruption leads to obesity, diabetes, and hypertension. A synthetic high-affinity agonist, [d-Tyr6,β-Ala11,Phe13,Nle14]Bn(6-14), has been described, but it is nonselective for hBRS-3 over other Bn receptors; however, substitution of (R)- or (S)-amino-3-phenylpropionic acid (Apa) for β-Ala11 resulted in a modestly selective ligand. In the present study, we have attempted to develop a more selective hBRS-3 ligand by using two strategies: substitutions on phenyl ring of Apa11 and the substitution of other conformationally restricted amino acids into position 11 of [d-Tyr6,β-Ala11,Phe13,Nle14]Bn(6-14). Fifteen analogs were synthesized and affinities were determined for hBRS-3 and Bn receptors (hGRP-R and hNMB-R). Selective analogs were tested for their ability to activate each receptor by stimulating phospholipase C. One analog, [d-Tyr6,Apa-4Cl,Phe13,Nle14]Bn(6-14), retained high affinity for the hBRS-3 (Ki = 8 nM) and had enhanced selectivity (>230-fold) for hBRS-3 over hGRP-R or hNMB-R. This analog specifically interacted with hBRS-3, fully activated hBRS-3 receptors, and was a potent agonist at the hBRS-3 receptor. This enhanced selectivity should allow this analog to be useful for investigating the possible role of hBRS-3 in physiological or pathological processes.

Footnotes

  • doi:10.1124/jpet.104.066761.

  • ABBREVIATIONS: BRS-3, bombesin receptor subtype 3; Bn, bombesin; GRP, gastrin-releasing peptide; GRP-R, gastrin-releasing peptide receptor; NMB, neuromedin B; NMB-R, neuromedin B peptide receptor; FBS, fetal bovine serum; CCK, cholecystokinin; VIP, vasoactive intestinal peptide; PACAP, pituitary adenylate cyclase-activating peptide; Apa, aminopropionic acid; β-Ala, β-alanine; β-Asp, Boc-β-aspartic acid; Cl, chloro; β-AspBzlAmd, Boc-β-aspartic acid benzilamide; Nα-acetyl-Dap, 2-acetylamino,3-aminopropionic acid; Nα-benzoyl-Dap, 2-benzoylamino,3-aminopropionic acid; β-Dap, 2,3,diaminopropionic acid; β-Dap(Pr), 2,3-diaminopropionic acid-proline; Acpb4-Boc(R)-3-amino-3-(4-chlorobenzyl)-propionic acid; hBRS-3, human bombesin receptor subtype 3; CHO, Chinese hamster ovary; IP, inositol phosphates; Nle, norleucine.

    • Received February 9, 2004.
    • Accepted April 20, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 310 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 310, Issue 3
1 Sep 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Development of Bombesin Analogs with Conformationally Restricted Amino Acid Substitutions with Enhanced Selectivity for the Orphan Receptor Human Bombesin Receptor Subtype 3
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Development of Bombesin Analogs with Conformationally Restricted Amino Acid Substitutions with Enhanced Selectivity for the Orphan Receptor Human Bombesin Receptor Subtype 3

Samuel A. Mantey, David H. Coy, Laurence K. Entsuah and Robert T. Jensen
Journal of Pharmacology and Experimental Therapeutics September 1, 2004, 310 (3) 1161-1170; DOI: https://doi.org/10.1124/jpet.104.066761

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Development of Bombesin Analogs with Conformationally Restricted Amino Acid Substitutions with Enhanced Selectivity for the Orphan Receptor Human Bombesin Receptor Subtype 3

Samuel A. Mantey, David H. Coy, Laurence K. Entsuah and Robert T. Jensen
Journal of Pharmacology and Experimental Therapeutics September 1, 2004, 310 (3) 1161-1170; DOI: https://doi.org/10.1124/jpet.104.066761
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • H2S Overproduction and Colonic Hypomotility in DM
  • A Novel Long-Acting GLP-2, HM15912, for Short Bowel Syndrome
  • MIP3a in Progressive Renal Injury Associated With Obesity
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics